Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
US5476851A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 8, 1994 |
| Grant date | Dec 19, 1995 |
| Priority date | — |
| Expiry date | Sep 8, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to pyrazolo[3,4-g]quinoxaline compounds exhibiting protein tyrosine kinase inhibition activity of the formula: ##STR1## where: ------ may be a double bond; PA2 R, R.sub.2, R.sub.3 and R.sub.4 are as described in claim 1; PA2 a pharmaceutically acceptable salt thereof. More specifically, compounds of this invention are novel as selective inhibitors of the PDGF-R protein tyrosine kinase and can be applied as potential therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation. Further, the present invention provides pharmaceutical compositions and a method for treating such disorders comprising the administration to a patient of a PDGF receptor inhibiting effective amount of a pyrazolo[3,4-g]quinoxaline compound exhibiting protein tyrosine kinase inhibition activity. Processes for the preparation of pyrazolo[3,4-g]quinoxaline compounds are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.